The promise of any new therapy that can reduce COPD exacerbations is likely to have a large impact on many of our patients. Do you have a hypothesis as to why patients treated with mepolizumab in these trials had fewer annual moderate or severe exacerbations (the primary outcome), but there was no difference in patient-reported symptoms or health-related quality of life?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.